17 Comments
 

Based on the most helpful WSO content, if your ultimate goal is to land a Long/Short Hedge Fund (L/S HF) seat, both Equity Research (ER) and Investment Banking (IB) can serve as viable paths. However, there are key considerations to weigh:

Equity Research (ER):

  • Direct Relevance to Hedge Funds: ER is often seen as a more natural feeder into hedge funds, especially for roles focused on stock-picking and fundamental analysis. Your experience in biotech ER will give you deep sector expertise, which is highly valued by hedge funds.
  • Specialization: Staying in ER allows you to build a strong track record in biotech, which could make you an attractive candidate for biotech-focused hedge funds.
  • Career Ladder Challenges: ER has a less structured career ladder compared to IB. Promotions can be slower, and moving from associate to analyst can take anywhere from 2 to 8 years, depending on the firm and sector dynamics.

Investment Banking (IB):

  • Broader Skillset: IB provides a more comprehensive financial skillset, including transaction experience, which can be appealing to hedge funds that value deal exposure.
  • Faster Career Progression: IB offers a more rigid and predictable promotional structure, with clear timelines for moving from analyst to associate and beyond.
  • Exit Opportunities: While IB is a strong feeder into private equity, it can also lead to hedge fund roles, though typically for event-driven or activist strategies rather than fundamental L/S funds.

Recommendation:

If your passion lies in fundamental analysis and you enjoy diving deep into biotech, continuing in ER is likely the better path for a L/S HF role. Your biotech expertise will be a significant asset when pitching yourself to hedge funds. However, if you want to broaden your skillset or keep options open for other finance roles, transitioning to IB for full-time could be worth considering.

Ultimately, your decision should align with your long-term interests and the type of hedge fund strategy you aim to pursue.

Sources: Career Ladder: Equity Research vs. Investment Banking - (A Definitive Guide, Part 3), Exit-Ops: Equity Research vs. Investment Banking - (A Definitive Guide, Part 2), The Efficient Career Hypothesis: Almost All Jobs Are Priced In, https://www.wallstreetoasis.com/forum/equity-research/career-ladder-equity-research-vs-investment-banking-a-definitive-guide-part-3?customgpt=1, Work/Life Balance: Equity Research vs. Investment Banking - (A Definitive Guide, Part 1)

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

That’s interesting… have found that the best ER teams / places to learn completely differ from banking. ie UBS is great for research but banking is obviously in a miserable spot.

 

Done both. Had same amount of outreach from HHs/BD in both too. IB is much much better from a technical standpoint, but ER, especially in your sector, has way more intricacies than any other industry. If you’re set on pharma/biotech, I’d suggest ER more, otherwise do IB in case you want to broaden your horizons while having a better technical foundation.

 

Minus quis et quo ut ut est voluptatem iusto. Veniam sed dolorem doloremque autem non aut. Non possimus non quia qui aut aut. Facere quasi ea molestiae debitis nisi quidem impedit. Et dicta velit exercitationem.

Explicabo velit saepe amet et dolor. Quasi hic cum enim sint eaque aut laborum fugiat. Aut qui ea quis. Magnam eos veritatis est cumque quaerat. Quasi voluptate aut aut laboriosam enim sequi vero perspiciatis.

Reiciendis animi enim velit dolorum pariatur consequuntur optio. Excepturi ut expedita neque non autem. Sit beatae fugit vel reprehenderit. Odio similique adipisci accusantium et voluptatem et. Autem aliquam adipisci reprehenderit quaerat vero voluptatem. Mollitia et sit et sed enim.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • AQR Capital Management 97.1%
  • Citadel Investment Group 96.1%
  • Magnetar Capital 95.1%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • D.E. Shaw 98.0%
  • Blackstone Group 97.0%
  • Citadel Investment Group 96.0%
  • Millennium Partners 95.0%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 98.1%
  • D.E. Shaw 97.1%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.2%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (77) $191
  • Analysts (242) $181
  • Intern/Summer Associate (29) $145
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”